Cargando…
Ocrelizumab-induced alopecia areata—A series of five patients from Ontario, Canada: A case report
BACKGROUND: Ocrelizumab is a humanized monoclonal antibody that targets the CD20 antigen found on B-cells. It is indicated in the treatment of both relapsing–remitting multiple sclerosis and primary progressive multiple sclerosis. OBJECTIVE: The aim of this study is to report and describe the charac...
Autores principales: | Chin, Laura D, AbuHilal, Mohn’d |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233903/ https://www.ncbi.nlm.nih.gov/pubmed/32477559 http://dx.doi.org/10.1177/2050313X20919614 |
Ejemplares similares
-
Upadacitinib for the treatment of alopecia areata and severe atopic dermatitis in a paediatric patient: A case report
por: Bourkas, Adrienn N, et al.
Publicado: (2022) -
Alopecia areata and subsequent Marie Antoinette syndrome following
COVID-19 infection and vaccination: A case report
por: AlZahrani, Fatmah, et al.
Publicado: (2023) -
Rapid hair regrowth in an alopecia universalis patient with deucravacitinib: A case report
por: Oliel, Sarah, et al.
Publicado: (2023) -
Hydroxychloroquine for granuloma annulare: A case report on secondary hair growth in alopecia universalis
por: Osman, Selena, et al.
Publicado: (2023) -
Successful treatment of concomitant alopecia universalis and Crohn’s
disease with upadacitinib: A case report
por: Johnston, Leah A, et al.
Publicado: (2023)